{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-328100","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2025-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.508388+00:00","generated_at":"2026-05-16T12:26:05.278901+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FDA approves Cytokinetics' MYQORZO; Royalty Pharma to receive 4.5% royalty on sales up to $5B","bullets":["Royalty Pharma entitled to 4.5% royalty on MYQORZO sales up to $5B, decreasing to 1% above $5B.","Long-term capital of $225M fully drawn; launch capital of $225M with $50M drawn to date.","Royalty Pharma to receive $523M in quarterly repayments over 10 years (1.9x); $20M repaid through Sep 2025.","Following approval, Cytokinetics can draw additional $175M within 12 months, repayable at 1.9x over 10 years.","MYQORZO (aficamten) approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-328100","json":"https://secwatch.observer/filing/0001193125-25-328100.json","markdown":"https://secwatch.observer/filing/0001193125-25-328100.md","text":"https://secwatch.observer/filing/0001193125-25-328100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312525328100/0001193125-25-328100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312525328100/d35067d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:26:05.278901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}